Med Indite Communications

26 Mar Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

Posted at 10:59h in Blogs by admin 0 Comments

In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months with chemotherapy (platinum-based and non-platinum-based chemotherapy). # ARIEL4 study. (Ref: Kristeleit R et...

19 Mar Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

Posted at 11:53h in Blogs by admin 0 Comments

Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (HR for death,...

11 Mar Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

Posted at 10:45h in Blogs by admin 0 Comments

The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showed that resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream...

04 Jan Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

Posted at 07:15h in Blogs by admin 0 Comments

In patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of disease progression or death was lower with trastuzumab deruxtecan than trastuzumab emtansine [Hazard ratio - 0.28 (p<0.001)]. The corresponding overall survival rate was 94.1% and 85.9% after 12...

11 Dec Vaccine Booster Dose and Mortality Due to Covid-19

Posted at 09:23h in Blogs by admin 0 Comments

Participants who received a booster at least 5 months after a second dose of Covid-19 vaccine had 90% lower mortality due to Covid-19 than participants who did not receive a booster. The adjusted hazard ratio for death due to Covid-19 in the booster group, as...

20 Nov Next Generation Therapeutics for the Treatment of Myelofibrosis

Posted at 10:13h in Blogs by admin 0 Comments

Multiple non-JAK inhibitor-based therapies are being explored in pre-clinical and clinical settings for the treatment of myelofibrosis, targeting outside of the JAK-STAT pathway. (Ref: Tremblay D et al. Cells. 2021) #oncologyresearch https://www.linkedin.com/feed/update/urn:li:activity:6867852221321658368...

Our Blogs

26 Mar Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

19 Mar Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

11 Mar Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

04 Jan Trastuzumab Deruxtecan Superior to Trastuzumab Emtansine in Metastatic HER2-positive Breast Cancer

11 Dec Vaccine Booster Dose and Mortality Due to Covid-19

20 Nov Next Generation Therapeutics for the Treatment of Myelofibrosis

Accelerated approval of Polivy

Adagrasib (KRAS inhibitor) in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Brentuximab Vedotin Improves Overall Survival in Treatment Naïve, Advanced Stage Hodgkin’s Lymphoma

Capivasertib (AKT inhibitor) plus Fulvestrant Improves Survival in Aromatase Inhibitor Resistant, ER+/HER2- Advanced Breast Cancer

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Our Services

More Link

Recent Post